These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26086795)

  • 1. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy.
    Derda AA; Thum S; Lorenzen JM; Bavendiek U; Heineke J; Keyser B; Stuhrmann M; Givens RC; Kennel PJ; Schulze PC; Widder JD; Bauersachs J; Thum T
    Int J Cardiol; 2015 Oct; 196():115-22. PubMed ID: 26086795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.
    Roncarati R; Viviani Anselmi C; Losi MA; Papa L; Cavarretta E; Da Costa Martins P; Contaldi C; Saccani Jotti G; Franzone A; Galastri L; Latronico MV; Imbriaco M; Esposito G; De Windt L; Betocchi S; Condorelli G
    J Am Coll Cardiol; 2014 Mar; 63(9):920-7. PubMed ID: 24161319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Obstructive Hypertrophic Cardiomyopathy from Nonobstructive Hypertrophic Cardiomyopathy: Development and Validation of a Model Based on Electrocardiogram Features.
    Guo L; Ma Z; Yang W; Zhang F; Shao H; Liu L; Gao C; Tao L
    Glob Heart; 2023; 18(1):40. PubMed ID: 37547171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy.
    Kitow J; Derda AA; Beermann J; Kumarswarmy R; Pfanne A; Fendrich J; Lorenzen JM; Xiao K; Bavendiek U; Bauersachs J; Thum T
    Am J Physiol Heart Circ Physiol; 2016 Sep; 311(3):H707-12. PubMed ID: 27422984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertrophic obstructive and non-obstructive cardiomyopathy in Japan. Diagnosis of the disease with special reference to endomyocardial catheter biopsy.
    Kawai C; Sakurai T; Fujiwara H; Matsumori A; Yui Y
    Eur Heart J; 1983 Nov; 4 Suppl F():121-5. PubMed ID: 6686527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.
    Sedaghat-Hamedani F; Kayvanpour E; Tugrul OF; Lai A; Amr A; Haas J; Proctor T; Ehlermann P; Jensen K; Katus HA; Meder B
    Clin Res Cardiol; 2018 Jan; 107(1):30-41. PubMed ID: 28840316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating miR-499a-5p Is a Potential Biomarker of
    Baulina N; Pisklova M; Kiselev I; Chumakova O; Zateyshchikov D; Favorova O
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of MYH7, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy.
    Marsiglia JD; Credidio FL; de Oliveira TG; Reis RF; Antunes Mde O; de Araujo AQ; Pedrosa RP; Barbosa-Ferreira JM; Mady C; Krieger JE; Arteaga-Fernandez E; Pereira Ada C
    Am Heart J; 2013 Oct; 166(4):775-82. PubMed ID: 24093860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
    Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
    PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Dissection of Hypertrophic Cardiomyopathy with Myocardial RNA-Seq.
    Gao J; Collyer J; Wang M; Sun F; Xu F
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic diagnosis of hypertrophic cardiomyopathy using mass spectrometry DNA arrays and high resolution melting.
    Santos S; Lança V; Oliveira H; Branco P; Silveira L; Marques V; Brito D; Madeira H; Bicho M; Fernandes AR
    Rev Port Cardiol; 2011 Jan; 30(1):7-18. PubMed ID: 21425739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (β-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy.
    Weissler-Snir A; Hindieh W; Gruner C; Fourey D; Appelbaum E; Rowin E; Care M; Lesser JR; Haas TS; Udelson JE; Manning WJ; Olivotto I; Tomberli B; Maron BJ; Maron MS; Crean AM; Rakowski H; Chan RH
    Circ Cardiovasc Imaging; 2017 Feb; 10(2):. PubMed ID: 28193612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy.
    Sonnenschein K; Fiedler J; de Gonzalo-Calvo D; Xiao K; Pfanne A; Just A; Zwadlo C; Soltani S; Bavendiek U; Kraft T; Dos Remedios C; Cebotari S; Bauersachs J; Thum T
    Sci Rep; 2021 Jan; 11(1):1755. PubMed ID: 33469076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art.
    Angelopoulos A; Oikonomou E; Vogiatzi G; Antonopoulos A; Tsalamandris S; Georgakopoulos C; Papanikolaou P; Lazaros G; Charalambous G; Siasos G; Vlachopoulos C; Tousoulis D
    Curr Med Chem; 2021; 28(36):7400-7412. PubMed ID: 33820510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy.
    Núñez L; Gimeno-Blanes JR; Rodríguez-García MI; Monserrat L; Zorio E; Coats C; McGregor CG; Hernandez del Rincón JP; Castro-Beiras A; Hermida-Prieto M
    Circ J; 2013; 77(9):2358-65. PubMed ID: 23782526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy.
    Chida A; Inai K; Sato H; Shimada E; Nishizawa T; Shimada M; Furutani M; Furutani Y; Kawamura Y; Sugimoto M; Ishihara J; Fujiwara M; Soga T; Kawana M; Fuji S; Tateno S; Kuraishi K; Kogaki S; Nishimura M; Ayusawa M; Ichida F; Yamazawa H; Matsuoka R; Nonoyama S; Nakanishi T
    Heart Vessels; 2017 Jun; 32(6):700-707. PubMed ID: 27885498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCM.
    Li M; Chen X; Chen L; Chen K; Zhou J; Song J
    J Transl Med; 2018 Jun; 16(1):161. PubMed ID: 29885652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Levels of MicroRNAs in Hypertrophic Cardiomyopathy: The Relationship With Left Ventricular Hypertrophy, Left Atrial Dilatation and Ventricular Depolarisation-Repolarisation Parameters.
    Sonsöz MR; Yilmaz M; Cevik E; Orta H; Bilge AK; Elitok A; Onur I; Komurcu-Bayrak E
    Heart Lung Circ; 2022 Feb; 31(2):199-206. PubMed ID: 34088630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations.
    Kuster DW; Mulders J; Ten Cate FJ; Michels M; Dos Remedios CG; da Costa Martins PA; van der Velden J; Oudejans CB
    J Mol Cell Cardiol; 2013 Dec; 65():59-66. PubMed ID: 24083979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA expression profiles in familial hypertrophic cardiomyopathy with myosin-binding protein C3 (MYBPC3) gene mutations.
    Lin LR; Hu XQ; Lu LH; Dai JZ; Lin NN; Wang RH; Xie ZX; Chen XM
    BMC Cardiovasc Disord; 2022 Jun; 22(1):278. PubMed ID: 35717150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.